BACKGROUND:Trimethoprim-sulfamethoxazole (TS) prophylaxis is recommended for persons living with human immunodeficiency virus infection and acquired immunodeficiency syndrome in Africa. TS and the antimalarial combination sulfadoxine-pyrimethamine (SP) share mechanisms of action and resistance patterns, and concerns about the impact of TS resistance on SP efficacy have contributed to reluctance to implement TS prophylaxis in Africa. METHODS: To determine whether TS prophylaxis impairs SP efficacy for treatment of uncomplicated falciparum malaria, we conducted a randomized, controlled, open-label study of TS prophylaxis. Two hundred and forty children 5-15 years old were randomized in a 2 : 1 fashion to receive either thrice-weekly TS for 12 weeks or no prophylaxis and were treated with SP for subsequent episodes of malaria. The incidence of malaria, SP efficacy, and the prevalence of parasite mutations that confer antifolate drug resistance were measured. RESULTS:TS prophylaxis had a 99.5% protective efficacy against episodes of clinical malaria, with 97% efficacy against infection. Four SP treatment failures occurred in the control group, and none occurred in the TS group. No evidence was seen for selection by TS of antifolate resistance-conferring mutations in parasite dihydrofolate reductase or dihydropteroate synthase during subclinical infections. CONCLUSIONS: In this setting of low antifolate resistance, TS was highly effective in preventing falciparum malaria infection and disease and did not appear to select for SP-resistant parasites.
RCT Entities:
BACKGROUND:Trimethoprim-sulfamethoxazole (TS) prophylaxis is recommended for persons living with human immunodeficiency virus infection and acquired immunodeficiency syndrome in Africa. TS and the antimalarial combination sulfadoxine-pyrimethamine (SP) share mechanisms of action and resistance patterns, and concerns about the impact of TS resistance on SP efficacy have contributed to reluctance to implement TS prophylaxis in Africa. METHODS: To determine whether TS prophylaxis impairs SP efficacy for treatment of uncomplicated falciparum malaria, we conducted a randomized, controlled, open-label study of TS prophylaxis. Two hundred and forty children 5-15 years old were randomized in a 2 : 1 fashion to receive either thrice-weekly TS for 12 weeks or no prophylaxis and were treated with SP for subsequent episodes of malaria. The incidence of malaria, SP efficacy, and the prevalence of parasite mutations that confer antifolate drug resistance were measured. RESULTS: TS prophylaxis had a 99.5% protective efficacy against episodes of clinical malaria, with 97% efficacy against infection. Four SP treatment failures occurred in the control group, and none occurred in the TS group. No evidence was seen for selection by TS of antifolate resistance-conferring mutations in parasite dihydrofolate reductase or dihydropteroate synthase during subclinical infections. CONCLUSIONS: In this setting of low antifolate resistance, TS was highly effective in preventing falciparum malaria infection and disease and did not appear to select for SP-resistant parasites.
Authors: N J White; F Nosten; S Looareesuwan; W M Watkins; K Marsh; R W Snow; G Kokwaro; J Ouma; T T Hien; M E Molyneux; T E Taylor; C I Newbold; T K Ruebush; M Danis; B M Greenwood; R M Anderson; P Olliaro Journal: Lancet Date: 1999-06-05 Impact factor: 79.321
Authors: C V Plowe; O K Doumbo; A Djimde; K Kayentao; Y Diourte; S N Doumbo; D Coulibaly; M Thera; T E Wellems; D A Diallo Journal: Am J Trop Med Hyg Date: 2001 May-Jun Impact factor: 2.345
Authors: D Schellenberg; C Menendez; E Kahigwa; J Aponte; J Vidal; M Tanner; H Mshinda; P Alonso Journal: Lancet Date: 2001-05-12 Impact factor: 79.321
Authors: Jonathan Mermin; John Lule; John Paul Ekwaru; Samuel Malamba; Robert Downing; Ray Ransom; Frank Kaharuza; David Culver; Francis Kizito; Rebecca Bunnell; Aminah Kigozi; Damalie Nakanjako; Winnie Wafula; Robert Quick Journal: Lancet Date: 2004 Oct 16-22 Impact factor: 79.321
Authors: Christopher V Plowe; James G Kublin; Fraction K Dzinjalamala; Deborah S Kamwendo; Rabia A G Mukadam; Phillips Chimpeni; Malcolm E Molyneux; Terrie E Taylor Journal: BMJ Date: 2004-02-02
Authors: Drissa Coulibaly; Dapa A Diallo; Mahamadou A Thera; Alassane Dicko; Ando B Guindo; Abdoulaye K Koné; Yacouba Cissoko; Seydou Coulibaly; Abdoulaye Djimdé; Kirsten Lyke; Ogobara K Doumbo; Christopher V Plowe Journal: Am J Trop Med Hyg Date: 2002-12 Impact factor: 2.345
Authors: A H Kilian; T Jelinek; I Prislin; G Kabagambe; W Byamukama; G Mpigika; R Korte; F von Sonnenburg Journal: Trans R Soc Trop Med Hyg Date: 1998 Mar-Apr Impact factor: 2.184
Authors: Anna Dow; Dumbani Kayira; Michael Hudgens; Annelies Van Rie; Caroline C King; Sascha Ellington; Athena Kourtis; Abigail Norris Turner; Steven Meshnick; Zebrone Kacheche; Denise J Jamieson; Charles Chasela; Charles van der Horst Journal: Pediatr Infect Dis J Date: 2012-08 Impact factor: 2.129
Authors: Samuel Malamba; Taylor Sandison; John Lule; Arthur Reingold; Jordan Walker; Grant Dorsey; Jonathan Mermin Journal: Am J Trop Med Hyg Date: 2010-05 Impact factor: 2.345
Authors: Moses R Kamya; James Kapisi; Victor Bigira; Tamara D Clark; Stephen Kinara; Florence Mwangwa; Mary K Muhindo; Abel Kakuru; Francesca T Aweeka; Liusheng Huang; Prasanna Jagannathan; Jane Achan; Diane V Havlir; Philip J Rosenthal; Grant Dorsey Journal: AIDS Date: 2014-11-28 Impact factor: 4.177
Authors: C J Gill; V Mwanakasale; M P Fox; R Chilengi; M Tembo; M Nsofwa; V Chalwe; L Mwananyanda; D Mukwamataba; B Malilwe; D Champo; W B Macleod; D M Thea; D H Hamer Journal: Bull World Health Organ Date: 2008-12 Impact factor: 9.408
Authors: Anne F Gasasira; Moses R Kamya; Edwin O Ochong; Neil Vora; Jane Achan; Edwin Charlebois; Theodore Ruel; Fredrick Kateera; Denise N Meya; Diane Havlir; Philip J Rosenthal; Grant Dorsey Journal: Malar J Date: 2010-06-23 Impact factor: 2.979
Authors: Victoria Nakibuuka; Grace Ndeezi; Deborah Nakiboneka; Christopher M Ndugwa; James K Tumwine Journal: Malar J Date: 2009-10-24 Impact factor: 2.979